Deutsche Bank AG Purchases 5,747 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Deutsche Bank AG increased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 45.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,462 shares of the medical instruments supplier’s stock after purchasing an additional 5,747 shares during the quarter. Deutsche Bank AG owned approximately 0.08% of LeMaitre Vascular worth $1,701,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LMAT. Allspring Global Investments Holdings LLC lifted its position in shares of LeMaitre Vascular by 48.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock valued at $1,227,000 after acquiring an additional 4,330 shares during the period. Invesco Ltd. boosted its holdings in shares of LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock worth $16,124,000 after buying an additional 58,720 shares during the last quarter. Compass Planning Associates Inc bought a new position in LeMaitre Vascular during the fourth quarter valued at $567,000. Barclays PLC raised its position in shares of LeMaitre Vascular by 394.5% in the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in LeMaitre Vascular by 31.8% during the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier’s stock worth $9,385,000 after purchasing an additional 24,586 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LMAT has been the topic of several research analyst reports. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Lake Street Capital increased their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $98.14.

Insider Buying and Selling

In other news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company’s stock, valued at approximately $456,915.68. The trade was a 26.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 4,399 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total value of $374,354.90. Following the completion of the sale, the chief executive officer now owns 1,827,003 shares of the company’s stock, valued at $155,477,955.30. The trade was a 0.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 102,009 shares of company stock worth $8,721,836. Corporate insiders own 9.50% of the company’s stock.

LeMaitre Vascular Trading Up 2.9%

Shares of NASDAQ LMAT opened at $81.40 on Friday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 44.48, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58. The firm has a 50 day moving average of $84.26 and a 200 day moving average of $92.65.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $59.87 million during the quarter, compared to analysts’ expectations of $57.61 million. During the same quarter in the previous year, the company posted $0.44 EPS. The company’s quarterly revenue was up 12.0% on a year-over-year basis. Sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 40.40%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.